GlassScriptPhysician profile
Jacqlyn Whitby
NPI 1982317012
$2,081.47
in general payments reported to CMS, 2019-2025
21 companies · $823 in 2025
The $823 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $611 · 2024: $647 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $591.57 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.32 | 2023-2025 | Lifevest |
| Amgen INC. | $165.52 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $157.95 | 2023-2025 | |
| Abbott Laboratories | $128.11 | 2025 | Perclose Prostyle, Aveir |
| Merck Sharp & Dohme LLC | $126.46 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $123.29 | 2023-2024 | Xarelto |
| Atricure, INC. | $109.36 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.72 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $50.30 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $45.95 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $45.50 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $44.41 | 2023-2024 | Assure Wcd |
| Edwards Lifesciences Corporation | $41.74 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $36.67 | 2024-2025 | Evkeeza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.90 | 2024-2025 | Farxiga |
| Heartflow, INC. | $20.85 | 2025 | |
| Glaxosmithkline, LLC. | $18.40 | 2025 | Shingrix, Arexvy |
| Bridgebio Pharma, INC. | $16.62 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $16.18 | 2025 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $13.65 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqlyn Whitby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.